Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

Eli Lilly (LLY) stock in focus as the company projects earnings headwinds from IPR&D charges estimated at $1.57B for Q1 2025.

Hims & Hers Health, Inc. (HIMS) closed the latest trading day at $27.23, indicating a +1.57% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of ...